scholarly journals Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy

2021 ◽  
pp. 2003042
Author(s):  
Shengjun Xu ◽  
Sunbin Ling ◽  
Qiaonan Shan ◽  
Qianwei Ye ◽  
Qifan Zhan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Delivery System

scholarly journals Synthesis and Characterization of Chitosan-Based Nanodelivery Systems to Enhance the Anticancer Effect of Sorafenib Drug in Hepatocellular Carcinoma and Colorectal Adenocarcinoma Cells

Nanomaterials ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 497
Author(s):  
Umme Ruman ◽  
Kalaivani Buskaran ◽  
Giorgia Pastorin ◽  
Mas Jaffri Masarudin ◽  
Sharida Fakurazi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Drug Delivery ◽  
Cell Lines ◽  
Delivery System ◽  
Colorectal Adenocarcinoma ◽  
Dermal Fibroblast ◽  
Spherical Shape ◽  
Ht29 Cell ◽  
Normal Human Dermal Fibroblast ◽  
Cancer Management

The formation of two nanodelivery systems, Sorafenib (SF)-loaded chitosan (SF-CS) and their folate-coated (SF-CS-FA) nanoparticles (NPs), were developed to enhance SF drug delivery on human Hepatocellular Carcinoma (HepG2) and Colorectal Adenocarcinoma (HT29) cell lines. The ionic gelation method was adopted to synthesize the NPs. The characterizations were performed by DLS, FESEM, TEM, XRD, TGA, FTIR, and UV-visible spectroscopy. It was found that 83.7 ± 2.4% and 87.9 ± 1.1% of encapsulation efficiency; 18.2 ± 1.3% and 19.9 ± 1.4% of loading content; 76.3 ± 13.7 nm and 81.6 ± 12.9 nm of hydrodynamic size; 60–80 nm and 70–100 nm of TEM; and FESEM sizes of near-spherical shape were observed, respectively, for SF-CS and SF-CS-FA nanoparticles. The SF showed excellent release from the nanoparticles under pH 4.8 PBS solution, indicating a good delivery system for tumor cells. The cytotoxicity study revealed their better anticancer action towards HepG2 and HT29 cell lines compared to the free sorafenib. Moreover, both NPs systems showed negligible toxicity to normal Human Dermal Fibroblast adult cells (HDFa). This is towards an enhanced anticancer drug delivery system with sustained-release properties for better cancer management.

An Integrated Therapeutic Delivery System for Enhanced Treatment of Hepatocellular Carcinoma

2018 ◽  
Vol 28 (18) ◽  
pp. 1706600 ◽  
Author(s):  
Zhou Ye ◽  
Wen-Rui Wu ◽  
Yu-Fei Qin ◽  
Jing Hu ◽  
Chao Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Delivery System ◽  
Therapeutic Delivery

scholarly journals A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma

2020 ◽  
Vol 7 (17) ◽  
pp. 2001424 ◽  
Author(s):  
Yu Qi ◽  
Yanli Liu ◽  
Bingran Yu ◽  
Yang Hu ◽  
Nasha Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Genome Editing ◽  
Delivery System

Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma

Life Sciences ◽  
2018 ◽  
Vol 206 ◽  
pp. 10-21 ◽  
Author(s):  
Greeshma Tom ◽  
Sheena Philip ◽  
Rimal Isaac ◽  
P.K. Praseetha ◽  
S.G. Jiji ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Delivery System ◽  
Magnetic Nanoparticle ◽  
Nanoparticle Delivery

A novel targeted delivery system for drug-resistant hepatocellular carcinoma therapy

Nanoscale ◽  
2020 ◽  
Vol 12 (32) ◽  
pp. 17029-17044
Author(s):  
Li Xiao ◽  
Yang Hou ◽  
Huimin He ◽  
Sinan Cheng ◽  
Yifan Hou ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Targeted Therapy ◽  
Delivery System ◽  
Targeted Delivery ◽  
Drug Resistant ◽  
Efficient Approach ◽  
Targeted Delivery System

HCSP4-Lipo-DOX-miR101 is a novel and efficient approach for HCC targeted therapy with MDR inhibition in vitro and in vivo.

Sign in / Sign up

Export Citation Format

Share Document